The Parkinson’s Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challenge
Table 3
Average ON and OFF values and their changes in MDS-UPDRS and PDCS motor scores by disease type during levodopa challenge.
Disease type
Tremor-dominant PD
Rigid-akinetic PD
Mixed PD
Non-PD (other parkinsonian syndromes)
MDS-UPDRS OFF (points)
45.3 ± 15.3
43.3 ± 16.5
48.3 ± 15.4
44.3 ± 13.1
MDS-UPDRS ON (points)
31.3 ± 13.5
29.6 ± 17.00
35.3 ± 13.9
40.5 ± 13.5
MDS-UPDRS change (points)
−14.0 ± 10.6
−13.7 ± 10.3
−13.1 ± 10.5
−3.8 ± 2.4
MDS-UPDRS change (%)
−29.7 ± 20.6
−33.5 ± 21.6
−26.9 ± 16.7
−9.9 ± 8.3
PDCS OFF (points)
12.0 ± 5.8
14.0 ± 6.8
14.2 ± 5.7
14.8 ± 6.0
PDCS ON (points)
8.0 ± 5.4
8.8 ± 7.0
11.3 ± 5.8
14.1 ± 6.0
PDCS change (points)
−4.0 ± 3.8
−5.2 ± 4.7
−2.9 ± 3.2
−0.7 ± 1.0
PDCS change (%)
−33.0 ± 28.0
−42.0 ± 34.7
−21.6 ± 24.5
−5.6 ± 8.2
Correlation (Spearman’s rho) between changes in MDS-UPDRS (%) and PDCS (%)
0.806 ()
0.776 ()
0.685 ()
0.465 ()
Data are mean ± standard deviation. Assessments in OFF state were performed at least 12 hours after the discontinuation of any antiparkinsonian medication. Patients were reassessed 60 minutes after a single dose of 200–400 mg immediate-release formulation of levodopa/benserazide or in the best ON state. MDS-UPDRS = Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale; PD = Parkinson’s disease; PDCS = Parkinson’s Disease Composite Scale.
